8-KEarnings & ResultsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 18, 2017)

Filed April 18, 2017For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on April 18, 2017, to report its first-quarter financial results for the period ended April 2, 2017. The filing primarily consists of a press release and supplementary financial data, announcing the company's sales and earnings performance. Investors should review these documents to understand JNJ's operational and financial standing at the beginning of the fiscal year 2017. The key takeaway for investors is the company's reported sales and earnings for the first quarter. While the 8-K itself does not contain detailed analytical commentary, it serves as the official channel for disseminating these crucial financial metrics. The accompanying press release and supplementary data will provide the specific figures on revenue, profitability, and potentially segment performance, which are vital for assessing the company's trajectory and making informed investment decisions.

Key Highlights

  • 1Johnson & Johnson announced its first-quarter 2017 sales and earnings results on April 18, 2017.
  • 2The 8-K filing includes a press release detailing the Q1 2017 financial performance.
  • 3Supplementary unaudited comparative sales data and condensed consolidated statements of earnings are provided.
  • 4The reported period is the first quarter ended April 2, 2017.
  • 5This filing serves as the official notification of JNJ's Q1 2017 financial results.
  • 6Investors can find specific sales and earnings figures within the attached exhibits.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially announce and provide Johnson & Johnson's sales and earnings results for the first quarter ended April 2, 2017. It includes a press release and supplementary financial data for investor review.

The detailed financial figures, including sales and earnings, are located in the press release (Exhibit 99.15) and the unaudited comparative supplementary sales data and condensed consolidated statement of earnings (Exhibit 99.2O) attached to this 8-K filing.

Typically, this type of filing will disclose key financial metrics such as total revenue, net earnings, earnings per share (EPS), and potentially segment-specific sales performance (e.g., Pharmaceuticals, Medical Devices, Consumer Health). Specific figures are found in the attached press release and supplementary statements.

This particular 8-K filing focuses on reporting past results for the first quarter of 2017. Any forward-looking guidance would typically be mentioned within the accompanying press release, but it's not guaranteed and should be confirmed by reviewing Exhibit 99.15.